Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00476190 | ALL Adult Consortium Trial: Adult ALL Trial | completed | Phase 2 | 112 | Dana-Farber Cancer InstituteOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT03792633 | Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL | completed | Phase 2 | 106 | University of PennsylvaniaOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03384654 |
| completed |
| Phase 2 |
| 47 |
| Janssen Research & Development, LLCINDUSTRY |
| 10 |
| May 25, 2025 |
| clinicaltrials |
| NCT04325841 | Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children | completed | Phase 2 | 2 | Beijing Boren HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT04340167 | Study of Anti-CD22 CAR-T Cells Treating Leukemia Children | completed | Phase 2 | 14 | Beijing Boren HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT01350245 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | completed | Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05149378 | Venetoclax Based Regimen for R/R T-ALL | completed | Phase 2 | 25 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT02631746 | Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma | completed | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Mar 14, 2025 | clinicaltrials |
| NCT00719888 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | completed | Phase 2 | 135 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06865352 | Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 15 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT02396134 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02484430 | Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04312841 | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT02828358 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 4 | Feb 27, 2025 | clinicaltrials |
| NCT00390793 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | completed | Phase 2 | 107 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03088878 | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 95 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03367299 | Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia(LAL2317) | completed | Phase 2 | 149 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT04716075 | Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)(ACALLO) | completed | Phase 2 | 29 | Polish Lymphoma Research GroupNETWORK | 1 | Jan 16, 2025 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03575325 | Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia | completed | Phase 2 | 11 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT01266083 | WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 22 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT00285259 | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | completed | Phase 2 | 112 | Astellas Pharma IncINDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT04151706 | CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML | completed | Phase 2 | 7 | Robert LowskyOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04788472 | Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL | completed | Phase 2 | 28 | Zhejiang UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03788291 | Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | completed | Phase 2 | 39 | University of RochesterOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT01243190 | Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | completed | Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05557110 | Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL | completed | Phase 2 | 35 | Chen SuningOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02953301 | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)(RESMAIN) | completed | Phase 2 | 201 | 4SC AGINDUSTRY | 12 | Aug 30, 2024 | clinicaltrials |
| NCT02157181 | Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab | completed | Phase 2 | 89 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04605666 | CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies | completed | Phase 2 | 77 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT01199575 | Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 30 | University of California, San DiegoOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT03275636 | Haploidentical Donor vs mMUD in Hematological Malignancies(HAMLET) | completed | Phase 2 / Phase 3 | 98 | DKMS gemeinnützige GmbHOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04969601 | Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings(PACIFIC) | completed | Phase 1 / Phase 2 | 76 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT02199184 | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT04942730 | Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)(FluBuBe) | completed | Phase 2 | 50 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT01597219 | Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers(UK-Haplo) | completed | Phase 2 | 77 | University College, LondonOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT05433532 | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients | completed | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02100423 | Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 35 | Paolo Caimi, MDOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02340884 | A Pilot RCT of the PRISM Intervention for AYAs With Cancer | completed | Phase 2 | 92 | Seattle Children's HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04554485 | Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)(Blina-CELL) | completed | Phase 2 | 27 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03056339 | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT02420912 | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 | clinicaltrials |
| NCT03267030 | Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase | completed | Phase 2 | 55 | Birgitte Klug AlbertsenOTHER | 6 | Mar 15, 2024 | clinicaltrials |
| NCT01858740 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | completed | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT02435849 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients(ELIANA) | completed | Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 11 | Feb 13, 2024 | clinicaltrials |
| NCT05045443 | Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia(CurcumPedALL) | completed | Phase 2 | 30 | Ain Shams UniversityOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04956666 | A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)(ALL) | completed | Phase 2 | 75 | Institut de Recherches Internationales ServierOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT05028374 | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies | completed | Phase 2 | 119 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT03734601 | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jun 12, 2025source: clinicaltrials